CDH2 and glioblastoma: Our results showed that the treatment with E2 (10 nM) promoted: (1) changes in cell morphology and the structure of the actin cytoskeleton, (2) increased expression of mesenchymal markers such as vimentin and N-cadherin, and (3) increased migratory and invasive capacity of GBM cells.